Crinetics Pharmaceuticals, Inc.
CRNX evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $9.01B
- Lead Asset:
- crn01941 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for CRNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRNX
Crinetics Pharmaceuticals, Inc. (CRNX) is a biopharmaceutical company focused on developing small-molecule therapies for endocrine diseases, with a lead approved product for acromegaly and a pipeline targeting endocrine-related tumors.
Key risk: Single product revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$9.01B
Cash Runway
—
Lead Asset
crn01941 (Preclinical)
Next Catalyst
Patent_Expiry · Mar 25, 2044Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 265 clinical trials · 1 catalyst · 1 FDA decision for Crinetics Pharmaceuticals, Inc..
Crinetics Pharmaceuticals, Inc. (CRNX) is a biopharmaceutical company focused on developing small-molecule therapies for endocrine diseases, with a lead approved product for acromegaly and a pipeline targeting endocrine-related tumors.
- Lead product PALSONIFY™ (paltusotine) is FDA-approved for adults with acromegaly who had an inadequate response to surgery [sec · filed 2026-04-29].
- Net product revenue for PALSONIFY was $5.4 million in Q4 2025, with over 200 enrollment forms by end of December 2025 [news · published 2026-02-27].
- Cash, cash equivalents, and investment securities were approximately $1.4 billion after a January 2026 public offering [sec_mda · as of 2026-02-26].
- A Phase 2/3 study of atumelnant for ACTH-dependent Cushing's syndrome is expected to initiate in the first half of 2026 [news · published 2026-02-27].
- On July 6, 2026, Crinetics entered into a merger agreement with Vertex Pharmaceuticals, subject to conditions [sec_mda · as of 2026-08-03].
What works
- PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, providing a differentiated product [sec · filed 2026-04-29].
- The company has a strong cash position of approximately $1.4 billion as of January 2026, extending runway into 2029 [sec_mda · as of 2026-02-26].
- Crinetics has a pipeline including atumelnant for Cushing's syndrome and early-stage candidates like CRN09682 from its NDC platform [sec_mda · as of 2026-02-26].
What to weigh
- Net income was -$120.9M for the period ending June 30, 2026, indicating ongoing operating losses [latest reported financials].
- The company is heavily reliant on a single approved product (PALSONIFY) for current revenue, with pipeline assets still in clinical development [sec · filed 2026-04-29].
- Forward-looking statements highlight risks including commercialization challenges, regulatory approvals, and competitive pricing [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
PALSONIFY is FDA-approved for acromegaly
“PALSONIFY TM (paltusotine), is the first once-daily, oral treatment approved by the Food and Drug Administration ("FDA") for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.”
SEC filings · April 29, 2026
Q4 2025 PALSONIFY revenue and enrollment
“PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December”
News · February 27, 2026
Cash position after January 2026 offering
“Immediately after the completion of this offering, our cash, cash equivalents and investment securities was approximately $1.4 billion.”
SEC MD&A · February 26, 2026
Merger agreement with Vertex
“On July 6, 2026, we entered into the Merger Agreement with Vertex and Merger Sub.”
SEC MD&A · August 3, 2026
Catalyst timeline
- 2044-03-25 · Patent_Expiry · PALTUSOTINE HYDROCHLORIDE — Patent expiry for paltusotine hydrochloride, which could affect long-term exclusivity.
Risks & what to watch (3)›
Key risks
- Single product revenue — Revenue is currently dependent on PALSONIFY, with no other approved products; pipeline candidates are in early-to-mid stages [sec · filed 2026-04-29].
- Operating losses — Net loss of $120.9M for the six months ended June 30, 2026, reflecting high R&D and commercialization costs [latest reported financials].
- Merger execution risk — The merger with Vertex is subject to conditions and may face integration or regulatory hurdles [sec_mda · as of 2026-08-03].
What to watch
- Initiation of the Phase 2/3 study of atumelnant for Cushing's syndrome in H1 2026 [news · published 2026-02-27].
- Progress of the Phase 1/2 study for CRN09682, the first NDC platform candidate [sec_mda · as of 2026-02-26].
- Completion of the merger with Vertex Pharmaceuticals and its impact on operations [sec_mda · as of 2026-08-03].
- PALSONIFY revenue growth and market adoption in the acromegaly space [news · published 2026-02-27].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Crinetics Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Crinetics Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.11 · 0% dilution
Lead: Approved
3 candidates
1 upcoming, next in ~6372d
0 buys · 3 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 15.7%
- Days to cover
- 13.0
- Shares short
- 14,170,153
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Crinetics Pharmaceuticals, Inc.?
Crinetics Pharmaceuticals, Inc. (CRNX) is a biopharmaceutical company focused on developing small-molecule therapies for endocrine diseases, with a lead approved product for acromegaly and a pipeline targeting endocrine-related tumors.
What is Crinetics Pharmaceuticals, Inc.'s lead drug candidate?
Crinetics Pharmaceuticals, Inc.'s most advanced tracked candidate is crn01941 (Preclinical) for veterinary use.
What is Crinetics Pharmaceuticals, Inc.'s next catalyst?
Crinetics Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA219070" — expected March 25, 2044.
Who is the CEO of Crinetics Pharmaceuticals, Inc.?
Dr. R. Scott Struthers Ph.D. is the chief executive officer of Crinetics Pharmaceuticals, Inc. (CRNX).
Where is Crinetics Pharmaceuticals, Inc. headquartered?
Crinetics Pharmaceuticals, Inc. (CRNX) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.